Alembic Pharmaceuticals Limited has received final approval from the United States Food and Drug Administration for its abbreviated new drug application (ANDA) for Fingolimod Capsules 0.5 mg, marking another addition to its US generics portfolio. The approval was granted on April 25, 2026, and allows the company to market a therapeutic equivalent to Gilenya, a branded drug originally developed by Novartis AG.

Fingolimod is indicated for the treatment of relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease in patients aged 10 years and above. Multiple sclerosis is a chronic neurological disorder requiring long-term treatment, making this segment relatively stable in terms of demand compared to acute therapy areas.

The US market for Fingolimod capsules is estimated at approximately USD 145 million for the 12 months ending December 2025, according to IQVIA data cited by the company. While the opportunity size is moderate compared to large blockbuster generics, the therapeutic category is considered complex, with fewer players and higher entry barriers than standard oral solids.

What is changing for Alembic Pharma is the gradual evolution of its US portfolio mix. With this approval, the company’s cumulative ANDA approvals have reached 237, including 219 final approvals and 18 tentative approvals. The steady build-up reflects a consistent pipeline strategy aimed at increasing presence in regulated markets while diversifying across therapeutic segments.

Why this approval matters lies in the nature of the product. Neurology-focused drugs typically require higher regulatory scrutiny and manufacturing precision. Entry into such segments indicates improved capability in handling complex generics, which can potentially offer better pricing resilience compared to commoditised molecules facing intense competition. Additionally, products targeting chronic conditions tend to generate more predictable demand patterns.

From a broader industry context, Indian pharmaceutical companies have been shifting toward specialty and limited-competition generics to offset pricing pressure in the US market. The Fingolimod approval fits into this trend, where companies are prioritising value over volume in regulated geographies.

The company has communicated the development through its official regulatory filing, available on its disclosure platforms, reinforcing transparency around product pipeline progress and market expansion.

Market Impact on India

For Indian pharma exporters, such approvals reinforce confidence in the sector’s ability to move up the value chain in regulated markets. Continued pipeline execution supports export growth and strengthens India’s position as a global generics supplier.

Sector Impact

Within the pharmaceutical sector, the approval highlights the shift toward complex generics and specialty therapies. Companies with stronger regulatory track records and diversified pipelines are likely to sustain better margins amid ongoing pricing pressure in the US generics market.

Bull vs Bear Scenario

The bullish case is that Alembic can capture a meaningful share of the USD 145 million market, supported by limited competition and stable demand in the neurology segment. This could improve revenue visibility from the US business.

The bearish view focuses on competition risk and pricing pressure. Even in niche segments, entry of additional generic players over time can compress margins, limiting profitability despite approval wins.

Risk Section

Key risks include pricing erosion in the US generics market, regulatory scrutiny related to manufacturing compliance, and slower-than-expected market share gains. Dependence on timely product launches and distribution execution will also influence actual revenue realisation.

Overall, the Fingolimod approval strengthens Alembic Pharma’s regulated market presence and signals continued progress toward building a more specialised and diversified generics portfolio.